BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belley-Cote EP, Eikelboom JW. Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and End-Stage Renal Disease-First, Do No Harm. JAMA Netw Open 2020;3:e202237. [PMID: 32250429 DOI: 10.1001/jamanetworkopen.2020.2237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lau WL. Controversies: Stroke Prevention in Chronic Kidney Disease. J Stroke Cerebrovasc Dis 2021;30:105679. [PMID: 33640261 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105679] [Reference Citation Analysis]
2 Sy J, Hsiung JT, Edgett D, Kalantar-Zadeh K, Streja E, Lau WL. Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. Am J Nephrol 2021;52:199-208. [PMID: 33789276 DOI: 10.1159/000514753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kreutz R, Camm AJ, Rossing P. Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. Eur Heart J Suppl 2020;22:O78-86. [PMID: 33380946 DOI: 10.1093/eurheartj/suaa182] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Canaud B, Stephens MP, Nikam M, Etter M, Collins A. Multitargeted interventions to reduce dialysis-induced systemic stress. Clin Kidney J 2021;14:i72-84. [PMID: 34987787 DOI: 10.1093/ckj/sfab192] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]